MedTrace Logo

Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients

NCT00515489 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1882

Last updated 2011-05-19

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department. The effectiveness of risperidone in controlling acute psychotic symptomatology and incidence, severity and risk of psychomotor agitation in acute psychotic patients was also studied.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorders

Interventions

DRUG

Risperidone

as prescribed

Sponsors & Collaborators

  • Janssen-Cilag, S.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial · Janssen-Cilag, S.A.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Completion
2002-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515489 on ClinicalTrials.gov